Gijsbert Veerman
Vice President, Early Phase Oncology, Europe
Gijsbert Veerman, VP of Early Phase Oncology – Europe at Worldwide Clinical Trials, is an accomplished leader with over 30 years of experience in clinical research within the CRO environment. His work is mainly focused on early phase oncology. Gijsbert has deep scientific expertise and a strong strategic vision. This makes him a trusted advisor for advancing innovative cancer therapies from first-in-human studies through dose optimization. He ensures each clinical project achieves optimal dose selection, safety profiles, and efficacy data, while meeting the highest regulatory and scientific standards in European markets.
Ask Gijsbert a question
Submit an RFP. Ask a Question
Gijsbert actively collaborates with global and regional cross-functional teams, E.U. health authorities (including the EMA and national competent authorities),
and European research networks to align trial designs with stringent regulatory expectations. His expertise spans the full drug development lifecycle, with
specialization in phase I, phase I/II, and phase II oncology studies focused on novel therapeutic modalities, including multi-specific antibodies, antibody-drug
conjugates, targeted therapies, and immuno-oncology agents. He skillfully navigates the complexities of European clinical development pathways,
addressing critical challenges including patient safety, protocol optimization, and regulatory compliance.
Gijsbert has a proven track record, delivering more than 300 projects. He has led portfolio management for early phase oncology programs for small and mid-size biotech customers in Europe. His strategic approach covers dose-finding, dose-expansion, and dose optimization studies. These studies deliver key insights for asset development. Gijsbert uses innovative clinical trial management strategies.He balances scientific rigor with operational efficiency, ensuring strong site selection, patient enrollment, and data quality in pan-European trial networks.
Gijsbert's strategic thinking and creative problem-solving drive exceptional outcomes across complex clinical trials. His commitment to fostering scientific excellence extends beyond project delivery. He actively cultivates relationships with European KOLs, academic consortia, patient advocacy organizations, and regulatory authorities to shape the future of oncology research.
Before joining Worldwide Clinical Trials, Gijsbert held senior leadership positions at IQVIA and Syneos Health, where he built and scaled early phase oncology.
